Antibody decay, T cell immunity and breakthrough infections following two SARS-CoV-2 vaccine doses in inflammatory bowel disease patients treated with infliximab and vedolizumab von Lin, S, Kennedy, NA, Saifuddin, A, Sandoval, DM, Reynolds, CJ, Seoane, RC, Kottoor, SH, Pieper, FP, Lin, K-M, Butler, DK, Chanchlani, N, Nice, R, Chee, D, Bewshea, C, Janjua, M, McDonald, TJ, Sebastian, S, Alexander, JL, Constable, L, Lee, JC, Murray, CD, Hart, AL, Irving, PM, Jones, G-R, Kok, KB, Lamb, CA, Lees, CW, Altmann, DM, Boyton, RJ, Goodhand, JR, Powell, N, Ahmad, T

Volltext